Logo image
Studies on cellular and humoral immunity elicited by influenza A virus infection and vaccination
Dissertation   Open access

Studies on cellular and humoral immunity elicited by influenza A virus infection and vaccination

Christopher Edward Lopez
University of Iowa
Doctor of Philosophy (PhD), University of Iowa
Summer 2024
DOI: 10.25820/etd.007702
pdf
Christopher_Lopez_Final_Dissertation6.72 MBDownloadView
Open Access Free to read and download

Abstract

Influenza A virus (IAV) infections represent a serious public health threat and account for significant morbidity and mortality worldwide due to seasonal epidemics and periodic pandemics. Prevention and control of IAV infection is dependent on the host immune response, particularly the adaptive immune response which can be greatly aided through prior IAV exposure via infection or vaccination. While vaccination represents an important and efficacious countermeasure to combat IAV, present vaccines predominately provide protection against matched strains of IAV, generate little heterosubtypic protection against distinct unrelated IAV strains and are subject to antigen mismatch due to the continuous antigenic drift/shift of circulating strains. As a result, the IAV field has focused on the development of a universal IAV vaccine capable of providing long-term robust protection against multiple strains of IAV. Previously my laboratory has reported on a novel intranasally administered biocompatible polyanhydride [copolymers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH)] nanoparticle-based vaccine platform (IAV-nanovax) capable of inducing robust cellular and humoral immune responses resulting in protection against subsequent homologous and heterosubtypic IAV infections in both inbred and outbred populations of mice. However, using the IAV-nanovax platform to incorporate disparate antigens from different stains of IAV leading to immunity and protection has not been examined yet as our initial report utilized IAV-nanovax encapsulating hemagglutinin (HA) and nucleoprotein (NP) derived from an H1N1 strain (A/Puerto Rico/8/1934) (H1-nanovax). Here I report on the cellular and humoral immune responses induced and, protection afforded, by IAV-nanovax encapsulating disparate antigens derived from IAV H3N2 (A/Hong Kong/1/68) (H3-nanovax) alone in addition to examining the impact of combinatorial vaccination regimens utilizing both H1N1 and H3N2 antigens in comparison to our previously reported H1-nanovax vaccination regimen in mice. My findings demonstrate that the efficacy of i.n. administered H3-nanovax with either HA + NP, neuraminidase (NA) + NP, or matrix protein (M1) + NA from an H3N2 strain (A/Hong Kong/1/68) induces significant immunity and provides robust protection against homologous IAV infection, as well as protection against heterosubtypic IAV infection in an antigen dependent manner. Following this, examining combinatorial vaccination regimens more analogous to present IAV vaccines, I observe that vaccination regimens of H1-nanovax prime followed by H3-nanovax boost and vice versa as well as IAV-nanovax encapsulating HA and NP antigens from both H1 and H3 viruses induce similar cellular and humoral immunity and protection to H1 or H3-nanovax homologous prime + boost vaccination alone. Overall, the findings outlined in this dissertation advances our understanding of determinants of vaccine-induced immunity that define protection against IAV infection and demonstrate the ability of our laboratories polyanhydride nanovaccine platform to generate broad immunity and protection against IAV utilizing diverse antigenic payloads and its potential to serve as a universal IAV vaccine.
Influenza Microbiology Antibody B cells Resident Memory T cells Vaccine

Details

Metrics

5 File views/ downloads
23 Record Views
Logo image